Thoracic tumor effects on plasmatic coagulation: Role of hemeoxygenase-1

Patients with thoracic tumors were determined to have an abnormally increased carboxyhemoglobin concentration of 2.1 ± 0.6%, indicative of hemeoxygenase-1 upregulation. It was found that 84% of thoracic tumor patients had plasma clot strength that exceeded the 95% confidence interval value observed in normal subjects, and 44% of this hypercoagulable subgroup had carboxyhemefibrinogen formation. Future investigation of the role played by plasmatic hypercoagulability and hemeoxygenase-1 derived carboxyhemefibrinogen in the pathogenesis of thoracic tumor related thrombophilia is warranted.